368 related articles for article (PubMed ID: 16710476)
1. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.
Kaposi-Novak P; Lee JS; Gòmez-Quiroz L; Coulouarn C; Factor VM; Thorgeirsson SS
J Clin Invest; 2006 Jun; 116(6):1582-95. PubMed ID: 16710476
[TBL] [Abstract][Full Text] [Related]
2. [Comparative genomic classification of human hepatocellular carcinoma].
Kaposi-Novák P
Magy Onkol; 2009 Mar; 53(1):61-7. PubMed ID: 19318328
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer.
Coulouarn C; Factor VM; Thorgeirsson SS
Hepatology; 2008 Jun; 47(6):2059-67. PubMed ID: 18506891
[TBL] [Abstract][Full Text] [Related]
4. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.
Ke AW; Shi GM; Zhou J; Wu FZ; Ding ZB; Hu MY; Xu Y; Song ZJ; Wang ZJ; Wu JC; Bai DS; Li JC; Liu KD; Fan J
Hepatology; 2009 Feb; 49(2):491-503. PubMed ID: 19065669
[TBL] [Abstract][Full Text] [Related]
5. u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma.
Tavian D; De Petro G; Benetti A; Portolani N; Giulini SM; Barlati S
Int J Cancer; 2000 Sep; 87(5):644-9. PubMed ID: 10925356
[TBL] [Abstract][Full Text] [Related]
6. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
Hepatology; 1997 Apr; 25(4):862-6. PubMed ID: 9096589
[TBL] [Abstract][Full Text] [Related]
7. C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization.
Wu YM; Liu CH; Huang MJ; Lai HS; Lee PH; Hu RH; Huang MC
Cancer Res; 2013 Sep; 73(17):5580-90. PubMed ID: 23832667
[TBL] [Abstract][Full Text] [Related]
8. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma.
Orimo T; Ojima H; Hiraoka N; Saito S; Kosuge T; Kakisaka T; Yokoo H; Nakanishi K; Kamiyama T; Todo S; Hirohashi S; Kondo T
Hepatology; 2008 Dec; 48(6):1851-63. PubMed ID: 18937283
[TBL] [Abstract][Full Text] [Related]
9. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
[TBL] [Abstract][Full Text] [Related]
10. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma.
Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
Hepatology; 1997 Mar; 25(3):619-23. PubMed ID: 9049208
[TBL] [Abstract][Full Text] [Related]
11. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway.
Tan S; Li R; Ding K; Lobie PE; Zhu T
FEBS Lett; 2011 Jul; 585(14):2229-34. PubMed ID: 21658389
[TBL] [Abstract][Full Text] [Related]
12. The HOX gene network in hepatocellular carcinoma.
Cillo C; Schiavo G; Cantile M; Bihl MP; Sorrentino P; Carafa V; D' Armiento M; Roncalli M; Sansano S; Vecchione R; Tornillo L; Mori L; De Libero G; Zucman-Rossi J; Terracciano L
Int J Cancer; 2011 Dec; 129(11):2577-87. PubMed ID: 21626505
[TBL] [Abstract][Full Text] [Related]
13. Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma.
Ivanovska I; Zhang C; Liu AM; Wong KF; Lee NP; Lewis P; Philippar U; Bansal D; Buser C; Scott M; Mao M; Poon RT; Fan ST; Cleary MA; Luk JM; Dai H
PLoS One; 2011; 6(9):e24582. PubMed ID: 21949730
[TBL] [Abstract][Full Text] [Related]
14. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma.
Cheng J; Xie HY; Xu X; Wu J; Wei X; Su R; Zhang W; Lv Z; Zheng S; Zhou L
Cancer Lett; 2011 Nov; 310(1):35-45. PubMed ID: 21763068
[TBL] [Abstract][Full Text] [Related]
15. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival.
Roessler S; Long EL; Budhu A; Chen Y; Zhao X; Ji J; Walker R; Jia HL; Ye QH; Qin LX; Tang ZY; He P; Hunter KW; Thorgeirsson SS; Meltzer PS; Wang XW
Gastroenterology; 2012 Apr; 142(4):957-966.e12. PubMed ID: 22202459
[TBL] [Abstract][Full Text] [Related]
16. MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met.
Korhan P; Erdal E; Atabey N
Biochem Biophys Res Commun; 2014 Aug; 450(4):1304-12. PubMed ID: 25058462
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1.
Muñoz Ú; Puche JE; Hannivoort R; Lang UE; Cohen-Naftaly M; Friedman SL
Mol Cancer Res; 2012 Sep; 10(9):1216-27. PubMed ID: 22859706
[TBL] [Abstract][Full Text] [Related]
18. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway.
Xu Z; Hu J; Cao H; Pilo MG; Cigliano A; Shao Z; Xu M; Ribback S; Dombrowski F; Calvisi DF; Chen X
Exp Mol Med; 2018 Jan; 50(1):e417. PubMed ID: 29303510
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.
Yang X; Zhang XF; Lu X; Jia HL; Liang L; Dong QZ; Ye QH; Qin LX
Hepatology; 2014 May; 59(5):1874-85. PubMed ID: 24259426
[TBL] [Abstract][Full Text] [Related]
20. Comparative and integrative functional genomics of HCC.
Lee JS; Thorgeirsson SS
Oncogene; 2006 Jun; 25(27):3801-9. PubMed ID: 16799621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
